Skip to main content
European Medicines Agency's logo Go to homepage

Main navigation

  • Medicines
    • Find medicine
    • Therapeutic areas: latest updates
    • Download medicine data
    • What we publish on medicines and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Medical devices
    • Herbal products
  • Veterinary regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    • Overview
    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    • Overview
    • News
    • Events
    • What's new
    • Committee highlights
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    • Overview
    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    • Overview
    • What we do
    • Who we are
    • How we work
    • Fees
    • Support to SMEs
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • Contacts
  1. Home
  2. Medicines
  3. Takhzyro - opinion on variation to marketing authorisation

Takhzyro - opinion on variation to marketing authorisation

Opinion

EMA has issued an opinion on a change to this medicine's authorisation.

lanadelumab
Post-authorisationHuman

Page contents

  • Opinion
  • Key facts
  • News on Takhzyro
  • More information on Takhzyro

Opinion

On 14 September 2023 , the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Takhzyro. The marketing authorisation holder for this medicinal product is Takeda Pharmaceuticals International AG Ireland Branch.

The CHMP adopted an extension to the existing indication as follows:1

Takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 2 years and older.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.


1New text in bold, removed text as strikethrough

CHMP post-authorisation summary of positive opinion for Takhzyro (X-0032-G)

AdoptedReference Number: EMA/CHMP/400511/2023

English (EN) (130.05 KB - PDF)

First published: 15/09/2023
View

Key facts

Name of medicine
Takhzyro
EMA product number
EMEA/H/C/004806
Active substance
lanadelumab
International non-proprietary name (INN) or common name
lanadelumab
Therapeutic area (MeSH)
Angioedemas, Hereditary
Anatomical therapeutical chemical (ATC) code
B06AC05

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Marketing authorisation holder
Takeda Pharmaceuticals International AG Ireland Branch
Date of opinion
14/09/2023
Status
Positive

News on Takhzyro

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023
15/09/2023
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018
19/10/2018
New medicine for hereditary angioedema, a rare disease causing swelling beneath the skin
19/10/2018

More information on Takhzyro

  • Takhzyro
This page was last updated on 15/09/2023

Share this page

Back to top

Product emergency hotline

OUTSIDE WORKING HOURS

About us
What we do
Careers
Committees & working parties
Regulatory network
European experts
Languages
Frequently asked questions
Glossaries
About this website
Cookies
Website data protection notice
Data protection at EMA
Search tips
Access to documents
Contacts
Send a question
EMA Service Desk (system support)
Services and databases

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us
Postal address and deliveries
Business hours and holidays

  • RSS Feed
  • Bluesky
  • YouTube
  • LinkedIn
© 1995 - 2025 European Medicines Agency
European Union agencies network
An agency of the European Union